Skip to main content
Log in

Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Excessive bodyweight gain was reported during the 1950s as an adverse effect of typical antipsychotic drug treatment, but the magnitude of bodyweight gain was found to be higher with the atypical antipsychotic drugs that were introduced after 1990. Clozapine and olanzapine produce the greatest bodyweight gain, ziprasidone and aripiprazole have a neutral influence, and quetiapine and risperidone cause an intermediate effect. In the CATIE study, the percentage of patients with bodyweight gain of >7% compared with baseline differed significantly between the antipsychotic drugs, i.e. 30%, 16%, 14%, 12% and 7% for olanzapine, quetiapine, risperidone, perphenazine (a typical antipsychotic) and ziprasidone, respectively (p < 0.001).

Appetite stimulation is probably a key cause of bodyweight gain, but genetic polymorphisms modify the bodyweight response during treatment with atypical antipsychotics.

In addition to nutritional advice, programmed physical activity, cognitive-behavioural training and atypical antipsychotic switching, pharmacological adjunctive treatments have been assessed to counteract excessive bodyweight gain. In some clinical trials, nizatidine, amantadine, reboxetine, topiramate, sibutramine and metformin proved effective in preventing or reversing atypical antipsychotic-induced bodyweight gain; however, the results are inconclusive since few randomized, placebo-controlled clinical trials have been conducted. Indeed, most studies were short-term trials without adequate statistical power and, in the case of metformin, nizatidine and sibutramine, the results are contradictory. The tolerability profile of these agents is adequate.

More studies are needed before formal recommendations on the use of these drugs can be made. Meanwhile, clinicians are advised to use any of these adjunctive treatments according to their individual pharmacological and tolerability profiles, and the patient’s personal and family history of bodyweight gain and metabolic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Fig. 3
Table III
Table IV

Similar content being viewed by others

References

  1. Caffey Jr EM. Experiences with large scale interhospital cooperative research in chemotherapy. Am J Psychiatry 1961; 117(2): 713–9

    PubMed  Google Scholar 

  2. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21(3): 463–72

    Article  PubMed  CAS  Google Scholar 

  3. Baptista T, Araujo de Baptista E, NMK Ng Ying Kin, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–19

    Article  PubMed  CAS  Google Scholar 

  4. Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002; 38(4): 157–9

    Google Scholar 

  5. McEvoy JP, Lieberman JA, Stroup TS. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163(4): 600–10

    Article  PubMed  Google Scholar 

  6. Kerwin RW, Bolonna AA. Is clozapine antisuicidal? Expert Rev Neurother 2004; 4(2): 187–90

    Article  PubMed  CAS  Google Scholar 

  7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. N Engl J Med 2005; 353: 1209–23

    Article  PubMed  CAS  Google Scholar 

  8. Green A, Patel J, Goisman R, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224–35

    Article  PubMed  CAS  Google Scholar 

  9. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65(2): 267–72

    Article  Google Scholar 

  10. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; (1): CD005148

  11. Bray GA, Greenway FL. Current and potential drugs for treatment of drugs for treatment of obesity. Endocr Rev 1999; 20: 805–75

    Article  PubMed  CAS  Google Scholar 

  12. Meguid MM, Fetissiv SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843–57

    Article  PubMed  CAS  Google Scholar 

  13. Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition 2000; 16: 937–46

    Article  PubMed  CAS  Google Scholar 

  14. Schneider JE. Energy balance and reproduction. Physiol Behav 2004; 81: 289–317

    Article  PubMed  CAS  Google Scholar 

  15. Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc London B Biol Sci 2006; 316: 1251–63

    Article  CAS  Google Scholar 

  16. Baptista T, LaCruz A, Meza T, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiat 2001; 46: 829–34

    CAS  Google Scholar 

  17. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  18. Taylor DM. McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–32

    CAS  Google Scholar 

  19. Wetterling T. Body weight gain with atypical antipsychotics: a comparative review. Drug Saf 2001; 24: 59–73

    Article  PubMed  CAS  Google Scholar 

  20. McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National outcomes measurement study in schizophrenia. Can J Psychiatry 2003; 48: 689–94

    PubMed  Google Scholar 

  21. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68(4): 597–603

    Article  PubMed  CAS  Google Scholar 

  22. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90

    Article  PubMed  CAS  Google Scholar 

  23. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the reatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164(7): 1050–60

    Article  PubMed  Google Scholar 

  24. McEvoy JP, Daniel DG, Carson Jr WH, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41(11): 895–905

    Article  PubMed  Google Scholar 

  25. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29(4): 303–19

    Article  PubMed  CAS  Google Scholar 

  26. Koga M. Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. Seishin Shinkeigaku Zasshi 2003; 105(4): 473–88

    PubMed  Google Scholar 

  27. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161(8): 1324–33

    Article  PubMed  Google Scholar 

  28. Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163(7): 1276–9

    Article  PubMed  Google Scholar 

  29. Basson BR, Kinon BJ, Taylor CC. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62(4): 231–8

    Article  PubMed  CAS  Google Scholar 

  30. Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005; 5: 3–16

    Article  PubMed  CAS  Google Scholar 

  31. Beasley Jr CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58Suppl. 10: S13–7

    Google Scholar 

  32. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100

    Article  PubMed  CAS  Google Scholar 

  33. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25(3): 250–4

    Article  PubMed  CAS  Google Scholar 

  34. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Clin Psychiatry 2001; 62(2): 114–6

    Article  CAS  Google Scholar 

  35. Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003; 64(3): 316–20

    Article  PubMed  Google Scholar 

  36. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81

    Article  PubMed  CAS  Google Scholar 

  37. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10: 259–68

    Article  PubMed  CAS  Google Scholar 

  38. Kasper S, Müller-Spanh F. Review of quetiapine and its clinical applications in schizophrenia. Exp Opin Pharmacother 2000; 1: 783–801

    Article  CAS  Google Scholar 

  39. Buse J, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164–70

    Article  PubMed  Google Scholar 

  40. Coccurello R, Caprioli A, Ghirardi O, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006; 186(4): 561–71

    Article  CAS  Google Scholar 

  41. Albaugh VL, Henry CR, Bello NT, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 2006 Jan; 14(1): 36–51

    Article  CAS  Google Scholar 

  42. Ader M, Kim SP, Catalano KJ. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54(3): 862–71

    Article  PubMed  CAS  Google Scholar 

  43. Baptista T, Araujo de Baptista E, Ying Kin NM, et al. Comparative effects of the antipsychotics sulphide or risperidone in rats: I. Bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 2002; 957(1): 144–51

    Article  PubMed  CAS  Google Scholar 

  44. Kalinichev M, Rourke C, Daniels AJ, et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 2005; 182(2): 220–31

    Article  CAS  Google Scholar 

  45. Cope MB, Nagy TR, Fernandez JR, et al. Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 2005; 29(6): 607–14

    Article  CAS  Google Scholar 

  46. Kalinichev M, Rourke C, Jones DN. Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine. Behav Pharmacol 2006; 17(3): 289–92

    Article  PubMed  CAS  Google Scholar 

  47. Kirk SL, Cahir M, Reynolds GP. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol 2006; 20(4): 577–9

    Article  PubMed  CAS  Google Scholar 

  48. Baptista T, La Cruz A, Mendoza S, et al. Endocrine and metabolic abnormalities involved in the obesity associated to typical antipsychotic drug administration. Pharmacopsychiatry 2001; 34: 223–31

    Article  PubMed  CAS  Google Scholar 

  49. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22(15): 6742–6

    PubMed  CAS  Google Scholar 

  50. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005; 30(1): 106–10

    Article  PubMed  CAS  Google Scholar 

  51. Birkas Kovats D, Palik E, Faludi G, et al. Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacol Hung 2005; 7(3): 132–9

    PubMed  Google Scholar 

  52. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007; 61(1): 54–8

    Article  PubMed  CAS  Google Scholar 

  53. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004; 172(2): 230–2

    Article  CAS  Google Scholar 

  54. Palik E, Birkas KD, Faludi G, et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 68Suppl. 1: S60–4

    Article  PubMed  CAS  Google Scholar 

  55. Theisen FM, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 12(10): 1411–6

    Article  CAS  Google Scholar 

  56. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005; 44(9): 925–33

    Article  PubMed  Google Scholar 

  57. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006; 20(1): 75–9

    Article  PubMed  CAS  Google Scholar 

  58. Rasgon NL, Reynolds MF, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005; 89: 217–25

    Article  PubMed  Google Scholar 

  59. Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship with body weight regulation. Pharmacol Biochem Behav 1999; 62: 409–17

    Article  PubMed  CAS  Google Scholar 

  60. Bergemann N, Mundt C, Parzer P, et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005; 73: 357–66

    Article  PubMed  Google Scholar 

  61. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003; 28: 519–26

    Article  CAS  Google Scholar 

  62. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000; 68: 29–39

    Article  PubMed  CAS  Google Scholar 

  63. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–22

    Article  PubMed  CAS  Google Scholar 

  64. Baptista T, Araujo de Baptista E, Beaulieu S, et al. Comparative effects of sulpiride or risperidone in rats. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1305–11

    Article  PubMed  CAS  Google Scholar 

  65. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacol 2007; 32: 765–72

    Article  CAS  Google Scholar 

  66. Sharpe JK, Byrne NM, Stedman TJ, et al. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105(4): 612–5

    Article  PubMed  Google Scholar 

  67. Sharpe JK, Stedman TJ, Byrne NM, et al. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006; 40(9): 810–4

    Article  PubMed  Google Scholar 

  68. Virkkunen M, Wahlbeck K, Rissanen A, et al. Decrease of energy expenditure causes weight increase in olanzapine treatment: a case study. Pharmacopsychiatry 2002; 35(3): 124–6

    Article  PubMed  CAS  Google Scholar 

  69. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162(1): 118–23

    Article  PubMed  Google Scholar 

  70. Fan X, Anderson EJ, Copeland PM, et al. Higher fasting insulin is associated with increased resting expenditure in nondiabetic schizophrenia patients. Biol Psychiatry 2006; 60(12): 1372–7

    Article  PubMed  CAS  Google Scholar 

  71. Monda M, Viggiano A, Viggiano A, et al. Clozapine blocks sympathetic and thermogenic reactions induced by orexin A in rats. Physiol Res 2004; 53(5): 507–13

    PubMed  CAS  Google Scholar 

  72. Monda M, Viggiano A, Viggiano A, et al. Quetiapine lowers sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Neuropeptides 2006 Oct; 40(5): 357–63

    Article  PubMed  CAS  Google Scholar 

  73. Olajossy-Hilkesberger L, Godlewska B, Marmurowska-Michalowskal H, et al. Antipsychotic-induced weight gain: pharmacogenetic studies. Psychiatr Pol 2006; 40(5): 1009–20

    PubMed  Google Scholar 

  74. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7(6): 863–87

    Article  PubMed  Google Scholar 

  75. Ruano G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapine-and risperidone-treated patients. Mol Psychiatry 2007; 12(5): 474–82

    PubMed  CAS  Google Scholar 

  76. Bray GA. Noradrenergic, serotonergic, antiepileptic and herbal drugs. In: Hofbauer KG, Keller U, Boss O, editors. Pharmacotherapy of obesity. Boca Raton (FL): CRC Press, 2004: 267–84

    Chapter  Google Scholar 

  77. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20(6): 716–7

    Article  PubMed  CAS  Google Scholar 

  78. Carpenter LL, Schecter JM, Sinischalchi J, et al. A case series describing orlistat use in patients on psychotropic medications. Med Health R I 2004; 87(12): 375–7

    PubMed  Google Scholar 

  79. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight [letter]. Eur Psychiatry 2005; 20(7): 520

    Article  PubMed  Google Scholar 

  80. Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48(2): 167–8

    Article  PubMed  CAS  Google Scholar 

  81. Pae CU, Kim JJ, Lee KU, et al. Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. Hum Psychopharmacol 2003; 18(6): 453–6

    Article  PubMed  CAS  Google Scholar 

  82. Cavazzoni P, Tanaka Y, Roychowdhury SM, et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13(2): 81–5

    Article  PubMed  CAS  Google Scholar 

  83. Atmaca M, Kuloglu M, Tezcan E. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine induced weight gain. Human Psychopharmacol 2003; 18: 457–61

    Article  CAS  Google Scholar 

  84. Atmaca M, Kuloglu M, Tezcan E, et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacol 2004; 19: 37–40

    Article  CAS  Google Scholar 

  85. Assuncao SS, Ruschel SI, Rosa Lde C, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 2006; 28(4): 270–6

    Article  PubMed  Google Scholar 

  86. López-Mato A, Rovner J, Illa G, et al. Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration. Vertex 2003; 14(52): 85–96

    PubMed  Google Scholar 

  87. Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004; 14(4): 332–6

    Article  PubMed  CAS  Google Scholar 

  88. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine in patients with schizophrenia. Schizophr Res 2006; 82(1): 115–7

    Article  PubMed  Google Scholar 

  89. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159: 1058–60

    Article  PubMed  Google Scholar 

  90. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65: 766–71

    Article  PubMed  CAS  Google Scholar 

  91. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297–302

    Article  PubMed  Google Scholar 

  92. Poyurovsky M, Fuchs C, Pashinian A. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology 2007; 192(3): 441–8

    Article  PubMed  CAS  Google Scholar 

  93. Baptista T, Martinez J, Lacruz A. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006; 51(3): 192–6

    PubMed  Google Scholar 

  94. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive fist episode schizophrenia patients: a double blind placebo-controlled study. Am J Psychiatry 2008; 165: 352–8

    Article  PubMed  Google Scholar 

  95. Ko YH, Joe SH, Kim SH. Topiramate as an adjunctive treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28(4): 169–75

    Article  PubMed  CAS  Google Scholar 

  96. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25(3): 211–7

    Article  PubMed  CAS  Google Scholar 

  97. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacol 2003; 28: 527–9

    Article  CAS  Google Scholar 

  98. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162: 954–62

    Article  PubMed  Google Scholar 

  99. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115(2): 101–5

    Article  PubMed  CAS  Google Scholar 

  100. Borovicka MC, Fuller MA, Konicki E, et al. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Clin Psychiatry 2002; 63(4): 345–8

    Article  CAS  Google Scholar 

  101. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005; 15: 13–21

    Article  PubMed  CAS  Google Scholar 

  102. Graham KA, Gu H, Lieberman JA. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005; 162: 1744–6

    Article  PubMed  Google Scholar 

  103. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin in treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163(12): 2072–9

    Article  PubMed  Google Scholar 

  104. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99–108

    Article  PubMed  Google Scholar 

  105. Wu RR, Zhao JP, Jin H, et al. Life style intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185–93

    Article  PubMed  CAS  Google Scholar 

  106. Baptista T, Uzcátegui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159(1–2): 250–3

    Article  PubMed  CAS  Google Scholar 

  107. Baptista T, Rangel N, ElFakih Y. Rosiglitazone in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study. Society of Neuroscience Annual Meeting; 2007 Nov 3–7; San Diego (CA)

  108. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss [letter]. Can J Psychiatry 2000; 45(2): 198

    PubMed  CAS  Google Scholar 

  109. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40(12): 1364

    Article  PubMed  CAS  Google Scholar 

  110. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. J Clin Psychiatry 2002; 63(11): 1045

    Article  PubMed  Google Scholar 

  111. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005; 59(5): 613–5

    Article  PubMed  Google Scholar 

  112. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005; 27(3): 228–32

    Article  PubMed  Google Scholar 

  113. Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24(4): 374–8

    Article  PubMed  CAS  Google Scholar 

  114. Poyurovsky M, Pashinian A, Levi A, et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005; 20(2): 101–3

    Article  PubMed  Google Scholar 

  115. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11(2): 181–2

    Article  PubMed  CAS  Google Scholar 

  116. Bahk WM, Lee KU, Chae JH, et al. Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 2004; 58(2): 163–7

    Article  PubMed  CAS  Google Scholar 

  117. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159(4): 655–7

    Article  PubMed  Google Scholar 

  118. Chen CH, Chiu CC, Huang MC, et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. Epub 2007 Nov 17

  119. Baptista T, Kin NM, Beaulieu S. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions. Clin Pharmacokinet 2004; 43(1): 1–15

    Article  PubMed  CAS  Google Scholar 

  120. Aminoff MJ. Pharmacotherapy of Parkinson disease and other movement disorders. In: Katsung BG, editor. Basic and clinical pharmacology. New York: McGraw-Hill Companies, Inc., 2001: 523–38

    Google Scholar 

  121. Deleu D, North MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309

    Article  PubMed  CAS  Google Scholar 

  122. Keck Jr PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63 Suppl. 4: 3–11

    Google Scholar 

  123. Stenlöf K, Rössner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007; 9(3): 360–8

    Article  PubMed  CAS  Google Scholar 

  124. Migliardi G, D’Arrigo C, Santoro V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. ClinNeuropharmacol 2007; 30(2): 107–13

    Article  CAS  Google Scholar 

  125. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299–320

    Article  PubMed  CAS  Google Scholar 

  126. Abolfathi Z, Couture J, Vallee F, et al. A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J Pharm Pharm Sci 2004; 7(3): 345–9

    PubMed  CAS  Google Scholar 

  127. Park JY, Kim KA, Park PW, et al. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. Clin Ther 2004; 26(12): 2092–101

    Article  PubMed  CAS  Google Scholar 

  128. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Practice 1999; 49: 871–4

    CAS  Google Scholar 

  129. Bijl D. The serotonin syndrome. Neth J Med 2004; 62(9): 309–13

    PubMed  CAS  Google Scholar 

  130. Baptista T, Sandia I, LaCruz A, et al. Insulin counter-regulatory factors, fibrinogen and c-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007; 22(2): 69–76

    Article  PubMed  Google Scholar 

  131. Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine, and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 2002; 237: 23–33

    Article  PubMed  CAS  Google Scholar 

  132. Furuta S, Kamada E, Suzuky T, et al. Inhibition of drug metabolism in human liver microsomas by nizatidine, cimetidi e and omeprazole. Xenoviotica 2001; 31: 1–10

    Article  CAS  Google Scholar 

  133. Food and Drug Administration. Guidance for the clinical evaluationof weight control drugs. Rockville (MD): Food and DrugAdministration, 1996]

    Google Scholar 

  134. European Agency for the Evaluation of Medicinal ProductsCommittee for Proprietary Medicinal Products (CPMP). Clinicalinvestigation of drugs used in weight control. London: The European Agency for the Evaluation of Medicinal Products, 1997

  135. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369(9555): 71–7

    Article  PubMed  CAS  Google Scholar 

  136. Kalucky RS. Drug-induced weight gain. Drugs 1980; 19: 268–78

    Article  Google Scholar 

  137. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005; 25(3): 255–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This article was supported by Fondo Nacional de Ciencia, Tecnología e Investigación (FONACIT), Caracas, Venezuela, grant no. 2005-000-384. The authors have no other conflicts of interest that are directly relevant to the content of this review. The authors particularly thank Françoise Meyer for her editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Trino Baptista.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baptista, T., ElFakih, Y., Uzcátegui, E. et al. Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. CNS Drugs 22, 477–495 (2008). https://doi.org/10.2165/00023210-200822060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200822060-00003

Keywords

Navigation